Palo Alto - Paul Hastings LLP, a leading global law firm, announced today that it represented Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, in its $175.8 million underwritten public offering of common stock. Viking announced that it intends to use the net proceeds from the offering for continued development of its VK5211, VK2809 and VK0214 programs and for general research and development, working capital and general corporate purposes.
Corporate partners Jeff Hartlin and Samantha Eldredge led the Paul Hastings team, which also included associate Ed Chu. Paul Hastings previously represented Viking Therapeutics in its underwritten public offerings of common stock.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.